Ionis Halved Its Launch Guide and Moved Breakeven to 2029 — The Pipeline That Justified $86 Is Gone
TRYNGOLZA's first full quarter in sHTG produced $9 million and a guidance cut to ~$50 million; the two Phase III failures now cost a year of cash-flow timing.
IONS · Earnings Call · 2026-11-09
The Number That Moved
In July, Ionis told investors to expect $100–110 million of TRYNGOLZA revenue in 2026. On this call the company halved it. “For TRYNGOLZA, we are lowering our 2026 full year revenue guidance to approximately $50 million to reflect a more gradual launch ramp than we had anticipated.” — Brett Monia, Chief Executive Officer · 2026-11-09 That is not a rounding error — it is the first commercial year of the asset that underpins the entire equity story, the one management still frames as a multibillion-dollar peak sales opportunity of $3 billion-plus in the U.S. The rest of the quarter is a study in contrast. DAWNZERA did exactly what it was supposed to do: $37 million in Q3, up roughly 40% sequentially, $79 million year-to-date, with the $110–120 million full-year guide held. ZANVASTRO, the first FDA-approved disease-modifying therapy for Alexander disease, booked its first product revenue and the first patients received commercial treatment. Total revenue of $243 million in the quarter and $757 million year-to-date was up 55% and 64% respectively ex the prior-year sapablursen payment. And yet the stock sits roughly 63% below where it traded in early July, with the $2.8 billion effective net cash pile now the main thing standing between the company and a financing decision it would rather not make.Enthusiasm Was Never the Constraint
The company's own keyword set tells the story of the pivot. Last quarter the language was anticipation; this quarter it is execution mechanics: prescriber base, depth of prescribing, repeat prescribers. Roughly 1,500 prescribers wrote TRYNGOLZA through September, only about 24% wrote more than one script, and 33% of commercial lives had coverage policies in place. Management now talks about translating HCP enthusiasm into action — a phrase that implicitly concedes enthusiasm was not the binding constraint. The prior calls are the awkward comparison. In July, five weeks in: “Internally, we are absolutely meeting the expectations of the launch here, keeping in mind that we're only 4 or 5 weeks into this, so it's very early.” — Kyle Jenne, Head of Commercial or Commercial Executive · 2026-07-29 One quarter later the full-year number is cut in half and the culprit is a slower-than-expected launch ramp. Brett Monia's defense is that the demand signal is intact even if the revenue is not: “Demand is increasing for TRYNGOLZA. And we're also very pleased with the persistency that TRYNGOLZA is demonstrating.” — Brett Monia, Chief Executive Officer · 2026-11-09Fair as far as it goes — and it is the argument that was equally available in July, when the guide was still $100 million. Note also that in April, before the June approval, the commercial chief was already setting expectations low: “The trajectory, I think, is going to be modest at the beginning here in 2026.” — Kyle Jenne, President, Commercial Operations · 2026-04-29 The defensible read is that Ionis is building a genuinely new market — a new treatment paradigm in severe hypertriglyceridemia, where acute pancreatitis risk reduction is the selling point and cardiologists, endocrinologists and lipidologists have to be taught which patient to put on a monthly auto-injector. The less generous read is that a company with three launches in flight briefly mistook physician intent for a demand curve.It's really important to remember that we are 3 months into — these numbers represent 3 months into a launch, delivering a medicine that is providing benefit to patients that physicians have never had experience with before.